Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.62 |
| ▸ | FAP | Q12884 | 12/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.62 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160605 | 0.95 | DPP4 (0.60) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3155789 | 0.94 | DPP4 (0.63) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3160876 | 0.93 | DPP4 (0.62) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3166137 | 0.93 | DPP4 (0.74) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3165068 | 0.92 | DPP4 (0.74) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3165763 | 0.92 | DPP4 (0.64) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3160933 | 0.92 | DPP4 (0.64) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3160279 | 0.92 | DPP4 (0.75) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3160100 | 0.90 | DPP4 (0.76) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3150545 | 0.90 | DPP4 (0.75) | DPP4FAPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1862457-B1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-1862457-A2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SmithKline Beecham Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1406873-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7132443-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINEBEECHAM CORPORATION (US) | 2006-11-07 | — | — | US | disclosed |
| US-20040171848-A1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171848-A1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 13/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.